Peel Hunt Reiterates "Add" Rating for ConvaTec Group (LON:CTEC)

Key Points

• Peel Hunt has reaffirmed an "add" rating for ConvaTec Group (CTEC) with a target price of GBX 280 ($3.74), indicating a potential upside of 14.47% from the current stock price.
• Other analysts, including Deutsche Bank and JPMorgan Chase, have also given buy ratings, with target prices ranging from GBX 307 to GBX 315 ($4.10 to $4.21).
• ConvaTec Group's stock has a twelve-month price range between GBX 211.80 ($2.83) and GBX 311.20 ($4.16), reflecting volatility in its trading performance.

Peel Hunt reaffirmed their add rating on shares of ConvaTec Group (LON:CTEC - Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. Peel Hunt currently has a GBX 280 ($3.72) price target on the stock.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. reaffirmed an "overweight" rating and set a GBX 307 ($4.07) price objective on shares of ConvaTec Group in a report on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a GBX 315 ($4.18) price target on shares of ConvaTec Group in a report on Thursday, July 3rd.

ConvaTec Group Price Performance

Shares of LON:CTEC traded down GBX 2.70 ($0.04) during midday trading on Tuesday, reaching GBX 230.70 ($3.06). 10,209,894 shares of the company's stock were exchanged, compared to its average volume of 14,010,055. The company's 50 day simple moving average is GBX 270.11 and its two-hundred day simple moving average is GBX 259.08. The firm has a market capitalization of £5.87 billion, a PE ratio of 38.85, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. ConvaTec Group has a 12 month low of GBX 211.80 ($2.81) and a 12 month high of GBX 311.20 ($4.13). The company has a debt-to-equity ratio of 85.32, a quick ratio of 0.96 and a current ratio of 2.26.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.